학술논문
A Deep Learning-Based Assessment Pipeline for Intraepithelial and Stromal Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Carcinoma.
Document Type
Academic Journal
Author
Hamada K; Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan.; Murakami R; Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan. Electronic address: ryusukem@kuhp.kyoto-u.ac.jp.; Ueda A; Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan.; Kashima Y; Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osaka, Japan.; Miyagawa C; Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osaka, Japan.; Taki M; Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan.; Yamanoi K; Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan.; Yamaguchi K; Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan.; Hamanishi J; Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan.; Minamiguchi S; Department of Diagnostic Pathology, Kyoto University Graduate School of Medicine, Kyoto, Japan.; Matsumura N; Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osaka, Japan.; Mandai M; Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Source
Publisher: Elsevier Country of Publication: United States NLM ID: 0370502 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-2191 (Electronic) Linking ISSN: 00029440 NLM ISO Abbreviation: Am J Pathol Subsets: MEDLINE
Subject
Language
English
Abstract
Tumor-infiltrating lymphocytes (TILs) are associated with improved survival in patients with epithelial ovarian cancer. However, the evaluation of TILs has not been applied to routine clinical practice because of reproducibility issues. We developed two convolutional neural network models to detect TILs and to determine their spatial location in whole slide images, and established a spatial assessment pipeline to objectively quantify intraepithelial and stromal TILs in patients with high-grade serous ovarian carcinoma. The predictions of the established models showed a significant positive correlation with the number of CD8 + T cells and immune gene expressions. We demonstrated that patients with a higher density of intraepithelial TILs had a significantly prolonged overall survival and progression-free survival in multiple cohorts. On the basis of the density of intraepithelial and stromal TILs, we classified patients into three immunophenotypes: immune inflamed, excluded, and desert. The immune-desert subgroup showed the worst prognosis. Gene expression analysis showed that the immune-desert subgroup had lower immune cytolytic activity and T-cell-inflamed gene-expression profile scores, whereas the immune-excluded subgroup had higher expression of interferon-γ and programmed death 1 receptor signaling pathway. Our established evaluation method provides detailed and comprehensive quantification of intraepithelial and stromal TILs throughout hematoxylin and eosin-stained slides, and has potential for clinical application for personalized treatment of patients with ovarian cancer.
Competing Interests: Disclosure Statement K.Yamag. reported receiving personal fees from Dumsco Inc. outside the submitted work. J.H. reported receiving grants from Chugai Pharmaceutical during the conduct of the study; grants from Ono Pharma Foundation, Kinopharma, and Sumitomo Pharma outside the submitted work; and lecture fees from MSD outside the submitted work. N.M. reported receiving grants from AstraZeneca outside the submitted work; personal fees from AstraZeneca, Chugai Pharmaceutical, and Takeda Pharmaceutical outside the submitted work; and serving as a paid outside director of Takara Bio.
(Copyright © 2024. Published by Elsevier Inc.)
Competing Interests: Disclosure Statement K.Yamag. reported receiving personal fees from Dumsco Inc. outside the submitted work. J.H. reported receiving grants from Chugai Pharmaceutical during the conduct of the study; grants from Ono Pharma Foundation, Kinopharma, and Sumitomo Pharma outside the submitted work; and lecture fees from MSD outside the submitted work. N.M. reported receiving grants from AstraZeneca outside the submitted work; personal fees from AstraZeneca, Chugai Pharmaceutical, and Takeda Pharmaceutical outside the submitted work; and serving as a paid outside director of Takara Bio.
(Copyright © 2024. Published by Elsevier Inc.)